VIDEO: Radiation, trastuzumab combination ‘not recommended’ for HER2+ DCIS
In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, highlighted the results from the NSABP B-43 trial that included radiation therapy efficacy with or without trastuzumab in women with ductal carcinoma in situ who have undergone lumpectomy.
Abraham discussed details of the study, specifically the dosing and efficacy of trastuzumab for women with HER2-postive ductal carcinoma in situ (DCIS).
“The addition of trastuzumab to radiation treatment did not see the primary objective of the protocol, but it did achieve a ... statistically non-significant reduction of 19% ipsilateral recurrence. So, addition of trastuzumab to radiation treatment in HER2-positive DCIS is not recommended, based upon this study,” Abraham concluded.
- Cobleigh, MA et al. Abstract TPS666. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.